Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Cell and Gene Therapy Market CAGR Outlook And Future Development#_x000D_
The market for cell and gene therapies has experienced significant expansion in recent years. Its valuation is anticipated to increase from $21.33 billion in 2025 to $26.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.9%. In the past, this historical growth can be attributed to factors such as the limited accessibility of cell and gene therapies, the prevailing reliance on conventional treatment modalities, the high cost of early-generation therapies, the rising incidence of oncology and neurological disorders, and a shortage of specialized treatment centers._x000D_
_x000D_
The cell and gene therapy market is anticipated to experience significant expansion in the coming years. Its valuation is projected to reach $60.58 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. This projected growth during the forecast period is fueled by several factors, including the creation of sophisticated CAR-T and genome editing treatments, the proliferation of clinical studies and research initiatives, a greater embrace of personalized medical approaches, increasing governmental aid and financial backing for therapies targeting rare diseases, and the integration of digital solutions for tracking treatment and managing patients. Key developments expected during this period involve a rise in the uptake of CAR-T and stem cell therapies, increased capital expenditure in gene therapy for cancer and rare conditions, the development of individualized and specific cell-based treatments, an increase in hospitals and outpatient surgical centers providing advanced therapies, and the incorporation of genome editing and viral vector-based techniques into standard medical practice._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Cell and Gene Therapy Market Growth Drivers: What’s Behind The Acceleration?#_x000D_
The expansion of active clinical trials is anticipated to propel the future growth of the cell and gene therapy market. These trials are research studies involving human subjects, designed to assess the safety and efficacy of novel medical therapies, procedures, or diagnostic methods. They are crucial for the progress and evolution of cell and gene therapy, providing a secure and regulated setting for evaluating new treatments and gathering information on their safety and effectiveness. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), an organization based in the UK, reported that the number of pharmaceutical industry trials initiated in the UK grew for the second successive year, increasing from 411 in 2022 to 426 in 2023. Consequently, the increasing volume of active clinical trials is stimulating the expansion of the cell and gene therapy market._x000D_
_x000D_
#Cell and Gene Therapy Market Segment Landscape And Growth Outlook#_x000D_
The cell and gene therapy market covered in this report is segmented – _x000D_
_x000D_
1) By Product: Cell Therapy, Gene Therapy _x000D_
2) By Application: Oncology, Neurological Disorders, Other Applications _x000D_
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy_x000D_
2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy _x000D_
_x000D_
_x000D_
#Cell and Gene Therapy Market Trends: What’s Defining The Industry’s Next Phase?#_x000D_
Leading companies operating within the cell and gene therapy market are increasingly focusing on introducing agnostic systems to gain a competitive advantage. Agnostic systems are those designed to integrate with a variety of different cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, launched the Cell and Gene Therapy Integration Hub, a new platform-agnostic system created to improve connectivity across the cell and gene therapy (CGT) treatment journey, thereby enabling an enhanced patient and provider experience. This hub is powered by the company’s customer relationship management system and is engineered to expedite the benefits investigation process, offer a real-time view of therapy development and transportation status, and assist in coordinating patient support._x000D_
_x000D_
#Cell and Gene Therapy Market Competitive Landscape: Who Leads The Industry?#_x000D_
Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca _x000D_
_x000D_
#View The Full Cell and Gene Therapy Market Report:#_x000D_
_x000D_
#Cell and Gene Therapy Market Regional Split: Which Areas Are Fueling Growth?#_x000D_
North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model